184 related articles for article (PubMed ID: 27022066)
1. Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer.
Jones MR; Schrader KA; Shen Y; Pleasance E; Ch'ng C; Dar N; Yip S; Renouf DJ; Schein JE; Mungall AJ; Zhao Y; Moore R; Ma Y; Sheffield BS; Ng T; Jones SJ; Marra MA; Laskin J; Lim HJ
Ann Oncol; 2016 May; 27(5):801-6. PubMed ID: 27022066
[TBL] [Abstract][Full Text] [Related]
2. Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade.
Leenen FH; Yuan B
Hypertension; 2001 Mar; 37(3):981-4. PubMed ID: 11244027
[TBL] [Abstract][Full Text] [Related]
3. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.
Ruilope L
J Hypertens Suppl; 1997 Dec; 15(7):S15-20. PubMed ID: 9532516
[TBL] [Abstract][Full Text] [Related]
4. Dual renin-angiotensin system blockade restores blood pressure-renin dependency in individuals with low renin concentrations.
Azizi M; Bissery A; Bura-Rivière A; Ménard J
J Hypertens; 2003 Oct; 21(10):1887-95. PubMed ID: 14508195
[TBL] [Abstract][Full Text] [Related]
5. Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats.
Dai WJ; Funk A; Herdegen T; Unger T; Culman J
Stroke; 1999 Nov; 30(11):2391-8; discussion 2398-9. PubMed ID: 10548676
[TBL] [Abstract][Full Text] [Related]
6. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
Maillard MP; Würzner G; Nussberger J; Centeno C; Burnier M; Brunner HR
Clin Pharmacol Ther; 2002 Jan; 71(1):68-76. PubMed ID: 11823759
[TBL] [Abstract][Full Text] [Related]
7. Immune Activation following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study.
Titmuss E; Milne K; Jones MR; Ng T; Topham JT; Brown SD; Schaeffer DF; Kalloger S; Wilson D; Corbett RD; Williamson LM; Mungall K; Mungall AJ; Holt RA; Nelson BH; Jones SJM; Laskin J; Lim HJ; Marra MA
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982943
[TBL] [Abstract][Full Text] [Related]
8. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension.
Schepke M; Werner E; Biecker E; Schiedermaier P; Heller J; Neef M; Stoffel-Wagner B; Hofer U; Caselmann WH; Sauerbruch T
Gastroenterology; 2001 Aug; 121(2):389-95. PubMed ID: 11487548
[TBL] [Abstract][Full Text] [Related]
9. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients.
Pechère-Bertschi A; Nussberger J; Decosterd L; Armagnac C; Sissmann J; Bouroudian M; Brunner HR; Burnier M
J Hypertens; 1998 Mar; 16(3):385-93. PubMed ID: 9557932
[TBL] [Abstract][Full Text] [Related]
10. Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease.
von Vigier RO; Zberg PM; Teuffel O; Bianchetti MG
Eur J Pediatr; 2000 Aug; 159(8):590-3. PubMed ID: 10968237
[TBL] [Abstract][Full Text] [Related]
11. Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy?
Vogt L; Navis G; de Zeeuw D
J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S53-7. PubMed ID: 15938035
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans.
Belz GG; Butzer R; Kober S; Mutschler E
J Cardiovasc Pharmacol; 2002 Apr; 39(4):561-8. PubMed ID: 11904530
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.
Lacour C; Canals F; Galindo G; Cazaubon C; Segondy D; Nisato D
Eur J Pharmacol; 1994 Nov; 264(3):307-16. PubMed ID: 7698170
[TBL] [Abstract][Full Text] [Related]
14. [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving HH; Lehnert H; Brøchner-Mortensen J; Gomis R; Andersen S; Arner P
Ugeskr Laeger; 2001 Oct; 163(40):5519-24. PubMed ID: 11601118
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis.
Hope S; Brecher P; Chobanian AV
Am J Hypertens; 1999 Jan; 12(1 Pt 1):28-34. PubMed ID: 10075381
[TBL] [Abstract][Full Text] [Related]
16. Studies of the renal effects of angiotensin II receptor blockade: the confounding factor of acute water loading on the action of vasoactive systems.
Burnier M; Pechère-Bertschi A; Nussberger J; Waeber B; Brunner HR
Am J Kidney Dis; 1995 Jul; 26(1):108-15. PubMed ID: 7611241
[TBL] [Abstract][Full Text] [Related]
17. Irbesartan: review of pharmacology and comparative properties.
Adams MA; Trudeau L
Can J Clin Pharmacol; 2000; 7(1):22-31. PubMed ID: 10822210
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
Mazzolai L; Maillard M; Rossat J; Nussberger J; Brunner HR; Burnier M
Hypertension; 1999 Mar; 33(3):850-5. PubMed ID: 10082498
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice.
Dol F; Martin G; Staels B; Mares AM; Cazaubon C; Nisato D; Bidouard JP; Janiak P; Schaeffer P; Herbert JM
J Cardiovasc Pharmacol; 2001 Sep; 38(3):395-405. PubMed ID: 11486244
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman P; Nyström F; Hägg A; Lind L
J Hypertens; 2002 Apr; 20(4):657-63. PubMed ID: 11910301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
